Vitrolife AB
Company Profile
Business description
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient’s fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
Contact
Box 9080
Gothenburg400 92
SWET: +46 317218000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
1,151
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.60 | 3.30 | 0.04% |
| CAC 40 | 8,068.62 | 17.14 | -0.21% |
| DAX 40 | 24,186.49 | 108.12 | -0.45% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,649.03 | 54.13 | -0.56% |
| HKSE | 25,794.60 | 182.19 | -0.70% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,092.10 | 744.45 | -1.46% |
| NZX 50 Index | 13,412.49 | 5.58 | 0.04% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,646.20 | 2.30 | 0.03% |
| SSE Composite Index | 3,895.72 | 6.37 | 0.16% |